Fig. 6: In vivo efficacy study of ZIKV CC_FLE sE formulated in PCEP-R848 adjuvant in BALB/c mice. | Nature Communications

Fig. 6: In vivo efficacy study of ZIKV CC_FLE sE formulated in PCEP-R848 adjuvant in BALB/c mice.

From: Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk

Fig. 6: In vivo efficacy study of ZIKV CC_FLE sE formulated in PCEP-R848 adjuvant in BALB/c mice.

A Study design scheme. BALB/c mice (N = 6/group) received 20 µg of immunogen formulated in PCEP-R848 were inoculated via subcutaneous (SC) route. ZIKV Puerto Rico 2015 (2 × 106 TCID50) was used for challenge via SC route. B Day 35 sera ID50 titers (N = 6/group) against ZIKV H/PF/2013 RVP. The geometric mean of ID50 for each group is denoted in green font. C 1 DPI immune mouse serum virus load (VL) (N = 6/group), assayed as ZIKV RNA copy number/ml. D Lymph node VL on 10 DPI (N = 6/group). In the assays in (B), (C), and (D), data are presented as geometric mean values +/- geometric SD, with each sample test duplicated. E Inverse correlation of serum nAb titers and serum virus load, analyzed using Spearman nonparametric test, ***p = 0.0002. Unless specified, two-tailed Mann–Whitney U-test, was used for statistical comparison, with 95% confidence. Source data are provided as a Source Data file.

Back to article page